Zydus Lifesciences Limited (ZYDUSLIFE) Stock Forecast & Price Target

Compare

8 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZYDUSLIFE Analyst Ratings

Hold

0 Buy

1 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Zydus

Lifesciences Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZYDUSLIFE Stock 12 Month Forecast

Average Price Target

₹965.00

▲(3.87% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Zydus Lifesciences Limited in the last 3 months. The average price target is ₹965.00 with a high forecast of ₹965.00 and a low forecast of ₹965.00. The average price target represents a 3.87% change from the last price of ₹929.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"865":"₹865","1228":"₹1,228","955.75":"₹955.8","1046.5":"₹1,046.5","1137.25":"₹1,137.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":965,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹965.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":965,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹965.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":965,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹965.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[865,955.75,1046.5,1137.25,1228],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,991.75,989.6923076923077,987.6346153846154,985.5769230769231,983.5192307692307,981.4615384615385,979.4038461538462,977.3461538461538,975.2884615384615,973.2307692307693,971.1730769230769,969.1153846153846,967.0576923076923,{"y":965,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,991.75,989.6923076923077,987.6346153846154,985.5769230769231,983.5192307692307,981.4615384615385,979.4038461538462,977.3461538461538,975.2884615384615,973.2307692307693,971.1730769230769,969.1153846153846,967.0576923076923,{"y":965,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,991.75,989.6923076923077,987.6346153846154,985.5769230769231,983.5192307692307,981.4615384615385,979.4038461538462,977.3461538461538,975.2884615384615,973.2307692307693,971.1730769230769,969.1153846153846,967.0576923076923,{"y":965,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1227.54,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1098.91,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1068.36,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":990.5,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":963.61,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":962.62,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":962.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":959.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":866.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":877.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":990.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":948.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":991.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹965.00

Average Price Target₹965.00

Lowest Price Target₹965.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Damayanti Kerai

HSBC

₹920→₹965

Hold

3.87%

Upside

Reiterated

10/14/25

HSBC Keeps Their Hold Rating on Zydus Lifesciences Limited (ZYDUSLIFE)HSBC analyst Damayanti Kerai raised the price target on Zydus Lifesciences (ZYDUSLIF:IN) to INR965.00 (from INR920.00) while maintaining a Hold rating.

Kunal Dhamesha

Macquarie

₹1,365→₹1,110

Buy

19.48%

Upside

Reiterated

07/08/25

Zydus Lifesciences Limited (ZYDUSLIFE) Receives a Buy from Macquarie

Bansi Desai

J.P. Morgan

₹1,140→₹1,000

Hold

7.64%

Upside

Reiterated

05/21/25

Zydus Lifesciences (ZYDUSLIF:IN) PT Lowered to INR1,000 at JPMorganJPMorgan analyst Bansi Desai lowered the price target on Zydus Lifesciences (ZYDUSLIF:IN) to INR1,000.00 (from INR1,140.00) while maintaining a Neutral rating.

Alok Dalal

Jefferies

₹1,350→₹1,150

Buy

23.78%

Upside

Reiterated

05/21/25

Zydus Lifesciences (ZYDUSLIF:IN) PT Lowered to INR1,150 at JefferiesJefferies analyst Alok Dalal lowered the price target on Zydus Lifesciences (ZYDUSLIF:IN) to INR1,150.00 (from INR1,350.00) while maintaining a Buy rating.

Tausif Shaikh

Exane BNP Paribas

Not Ranked

Exane BNP Paribas

₹1,068→₹996

Hold

7.21%

Upside

Reiterated

05/20/25

Zydus Lifesciences (ZYDUSLIF:IN) PT Lowered to INR996 at BNP Paribas ExaneBNP Paribas Exane analyst Tausif Shaikh lowered the price target on Zydus Lifesciences (ZYDUSLIF:IN) to INR996.00 (from INR1,068.00) while maintaining a Neutral rating.

Anubhav Agarwal CFA

UBS

₹850

Sell

-8.51%

Downside

Reiterated

03/12/25

UBS Reiterates Sell Rating on Zydus Lifesciences (ZYDUSLIF:IN)UBS analyst Anubhav Agarwal reiterated a Sell rating and INR850.00 price target on Zydus Lifesciences (ZYDUSLIF:IN).

Abdulkader Puranwala

ICICI Securities

₹960→₹1,000

Hold

7.64%

Upside

Reiterated

02/06/25

Zydus Lifesciences (ZYDUSLIF:IN) PT Raised to INR1,000 at ICICI SecuritiesICICI Securities analyst Abdulkader Puranwala raised the price target on Zydus Lifesciences (ZYDUSLIF:IN) to INR1,000.00 (from INR960.00) while maintaining a Hold (3) rating.

Anshuman Gupta CFA

Investec

₹1,130→₹940

Sell

1.18%

Upside

Reiterated

02/05/25

Zydus Lifesciences (ZYDUSLIF:IN) PT Lowered to INR940 at InvestecInvestec analyst Anshuman Gupta lowered the price target on Zydus Lifesciences (ZYDUSLIF:IN) to INR940.00 (from INR1,130.00) while maintaining a Sell rating.

Saion Mukherjee

Nomura

₹1,030→₹1,140

Buy

22.71%

Upside

Upgraded

01/09/25

Nomura/Instinet Upgrades Zydus Lifesciences (ZYDUSLIF:IN) to BuyNomura/Instinet analyst Saion Mukherjee upgraded Zydus Lifesciences (ZYDUSLIF:IN) from Neutral to Buy with a price target of INR1,140.00 (from INR1,030.00).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Damayanti Kerai

HSBC

₹920→₹965

Hold

3.87%

Upside

Reiterated

10/14/25

Kunal Dhamesha

Macquarie

₹1,365→₹1,110

Buy

19.48%

Upside

Reiterated

07/08/25

Zydus Lifesciences Limited (ZYDUSLIFE) Receives a Buy from Macquarie

Bansi Desai

J.P. Morgan

₹1,140→₹1,000

Hold

7.64%

Upside

Reiterated

05/21/25

Alok Dalal

Jefferies

₹1,350→₹1,150

Buy

23.78%

Upside

Reiterated

05/21/25

Tausif Shaikh

Exane BNP Paribas

Not Ranked

Exane BNP Paribas

₹1,068→₹996

Hold

7.21%

Upside

Reiterated

05/20/25

Anubhav Agarwal CFA

UBS

₹850

Sell

-8.51%

Downside

Reiterated

03/12/25

UBS Reiterates Sell Rating on Zydus Lifesciences (ZYDUSLIF:IN)UBS analyst Anubhav Agarwal reiterated a Sell rating and INR850.00 price target on Zydus Lifesciences (ZYDUSLIF:IN).

Abdulkader Puranwala

ICICI Securities

₹960→₹1,000

Hold

7.64%

Upside

Reiterated

02/06/25

Anshuman Gupta CFA

Investec

₹1,130→₹940

Sell

1.18%

Upside

Reiterated

02/05/25

Saion Mukherjee

Nomura

₹1,030→₹1,140

Buy

22.71%

Upside

Upgraded

01/09/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zydus Lifesciences Limited

1 Month

xxx

Success Rate

2/3 ratings generated profit

Average Return

+0.77%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +0.77% per trade.

3 Months

xxx

Success Rate

2/2 ratings generated profit

Average Return

+6.10%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +6.10% per trade.

1 Year

Kunal DhameshaMacquarie

Success Rate

1/2 ratings generated profit

Average Return

+0.25%

reiterated a buy rating 5 months ago

Copying Kunal Dhamesha's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.25% per trade.

2 Years

xxx

Success Rate

1/2 ratings generated profit

Average Return

+0.25%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +0.25% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZYDUSLIFE Analyst Recommendation Trends

Rating

Mar 25

May 25

Jul 25

Aug 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZYDUSLIFE has received 5 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. ZYDUSLIFE average Analyst price target in the past 3 months is 965.00.

Each month's total comprises the sum of three months' worth of ratings.

ZYDUSLIFE Financial Forecast

ZYDUSLIFE Earnings Forecast

Next quarter’s earnings estimate for ZYDUSLIFE is ₹7.90 with a range of ₹6.70 to ₹9.10. The previous quarter’s EPS was ₹12.30. ZYDUSLIFE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ZYDUSLIFE has Performed in-line its overall industry.

ZYDUSLIFE Sales Forecast

Next quarter’s sales forecast for ZYDUSLIFE is ₹61.15B with a range of ₹57.75B to ₹63.32B. The previous quarter’s sales results were ₹61.23B. ZYDUSLIFE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ZYDUSLIFE has Performed in-line its overall industry.

ZYDUSLIFE Stock Forecast FAQ

What is IN:ZYDUSLIFE’s average 12-month price target, according to analysts?

Based on analyst ratings, Zydus Lifesciences Limited’s 12-month average price target is 965.00.

What is IN:ZYDUSLIFE’s upside potential, based on the analysts’ average price target?

Zydus Lifesciences Limited has 3.87% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Zydus Lifesciences Limited a Buy, Sell or Hold?

Zydus Lifesciences Limited has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

What is Zydus Lifesciences Limited’s share price target?

The average share price target for Zydus Lifesciences Limited is 965.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹965.00 ,and the lowest forecast is ₹965.00. The average share price target represents 3.87% Increase from the current price of ₹929.05.

What do analysts say about Zydus Lifesciences Limited?

Zydus Lifesciences Limited’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Zydus Lifesciences Limited?

To buy shares of IN:ZYDUSLIFE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Zydus Lifesciences Limited (ZYDUSLIFE) Stock Forecast & Price Target

ZYDUSLIFE Analyst Ratings

ZYDUSLIFE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zydus Lifesciences Limited

ZYDUSLIFE Analyst Recommendation Trends

ZYDUSLIFE Financial Forecast

ZYDUSLIFE Earnings Forecast

ZYDUSLIFE Sales Forecast

ZYDUSLIFE Stock Forecast FAQ

Detailed List of Analyst Forecasts